Jagsonpal Pharmaceuticals Limited has informed the Exchange about Buyback Letter of Offer
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jagsonpal Pharmaceuticals Limited has announced a buyback of up to 16,00,000 equity shares (2.38% of total paid-up capital) at ₹250 per share, for a total consideration up to ₹40 crores. The buyback runs from May 8 to May 14, 2026, via the tender offer route through BSE. The offer price represents a significant premium over the face value of ₹2 per share. Shareholders can tender their shares proportionally, with small shareholders getting a reserved category allocation. The buyback size is 18.35% of the company's aggregate paid-up capital and free reserves as per FY2025, within the statutory 25% limit. Settlement is scheduled for May 21, 2026.
The buyback offers shareholders an opportunity to exit at ₹250 per share, with the company returning capital. The high buyback price relative to face value suggests significant premium, which could support the stock price near the offer price during the tender period.